Back to Search
Start Over
Case Report of Erdheim-Chester Disease Successfully Treated with Pegylated Interferon: A Single-Center Experience.
- Source :
-
Cancer Research & Treatment . Jul2023, Vol. 55 Issue 3, p1053-1057. 5p. - Publication Year :
- 2023
-
Abstract
- Erdheim-Chester disease (ECD), also known as non-Langerhans cell histiocytosis, is a multi-systemic disease with unclear pathogenesis. Based on a small number of case studies, pegylated interferon-a (PEG-IFN-α) has been used as the front-line treatment option. However, there are limited data regarding administration of ropegylated-interferon α-2b (ROPEG-IFN-α 2b) for ECD patients. Herein, we report two cases of severe ECD treated with two types of PEG-IFN-α. One patient with heart and skeleton involvement and BRAF V600E mutation was treated with weekly PEG-IFN-a 2a. Another patient with bone involvement and no BRAF V600E mutation was administered monthly ROPEG-IFN-α 2b. The two types of PEG-IFN-α showed excellent disease control, excellent survival outcomes, and manageable toxicities in ECD patients. These results suggest that ROPEG-IFN-a 2b could be used equivalently to PEG-IFN-α 2a for management of advanced ECD. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 15982998
- Volume :
- 55
- Issue :
- 3
- Database :
- Academic Search Index
- Journal :
- Cancer Research & Treatment
- Publication Type :
- Academic Journal
- Accession number :
- 169934798
- Full Text :
- https://doi.org/10.4143/crt.2022.1535